Breast Cancer Excellence Forum

Breast Cancer

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Seth Wander, MD, PhD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD

Videos

Inavolisib for PIK3CA-Mutant Metastatic Breast Cancer

01/03/2025

Seth Wander , MD;

Kelly McCann , MD, PhD;

Janice Lu , MD, PhD;

Megan Kruse , MD;

In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the newest data on inavolisib from the INAVO120 trial.

In this video, a panel of...

01/03/2025

Oncology

Videos

Agents Targeting PI3K Signaling in HR-Positive Metastatic Breast Cancer

01/03/2025

Seth Wander , MD;

Kelly McCann , MD, PhD;

Janice Lu , MD, PhD;

Megan Kruse , MD;

In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the agents targeting PI3K signaling.

In this video, a panel of...

01/03/2025

Oncology

Videos

The PI3 Kinase Pathway in Metastatic HR-Positive Breast Cancer

01/02/2025

Seth Wander , MD;

Kelly McCann , MD, PhD;

Janice Lu , MD, PhD;

Megan Kruse , MD;

In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including an overview of the PI3 kinase pathway in cancer.

In this video, a panel of...

01/02/2025

Oncology

Demetria Smith-Graziani, MD, MPH, Winship Cancer Institute

Videos

Inavolisib vs Alpelisib Plus Fulvestrant For Patients With PIK3CA-Mutated Advanced Breast Cancer

09/24/2024

Demetria J. Smith-Graziani , MD, MPH;

Demetria Smith-Graziani, MD, MPH, describes the currently enrolling and ongoing INAVO121 trial, evaluating inavolisib vs alpelisib, both in combination with fulvestrant, for patients with PIK3CA-mutated, hormone receptor-positive,...

Demetria Smith-Graziani, MD,...

09/24/2024

Oncology

Videos

First-Line Capivasertib Plus Paclitaxel Fails to Improve OS in Metastatic Triple-Negative Breast Cancer

09/16/2024

Heather McArthur, MD, discusses results from the phase 3 CAPItello-290 trial which evaluated capivasertib plus paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer.

Heather McArthur, MD, discusses...

09/16/2024

Oncology

Videos

Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab Improves Survival in Early-Stage Triple-Negative Breast Cancer

09/15/2024

Peter Schmid , MD, PhD;

Peter Schmid, MD, PhD, discusses results from the phase 3 KEYNOTE-522 study which demonstrated significantly improved overall survival with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab for patients with...

Peter Schmid, MD, PhD, discusses...

09/15/2024

Oncology

Videos

Inavolisib Plus Palbociclib and Fulvestrant for Patients With Relapsed PIK3CA-Mutated Advanced Breast Cancer

09/03/2024

Demetria J. Smith-Graziani , MD, MPH;

Demetria Smith-Graziani, MD, MPH, shares insights from the results of the phase 3 INAVO120 study, evaluating the addition of inavolisib to palbociclib and fulvestrant for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced...

Demetria Smith-Graziani, MD,...

09/03/2024

Oncology

Erika Hamilton, MD, Sarah Cannon Research Institute

Videos

Trastuzumab Deruxtecan Maintains Superiority Over Trastuzumab Emtansine Among Patients With HER2-Positive Metastatic Breast Cancer

06/20/2024

Erika Hamilton, MD

Erika Hamilton, MD discusses the long-term analysis from the phase 3 DESTINY-Breast03 trial which reinforced the superiority of trastuzumab deruxtecan over trastuzumab emtansine for patients with HER2-positive metastatic breast cancer...

Erika Hamilton, MD discusses the...

06/20/2024

Oncology

Ruta Rao, MD; Seth Wander, MD, PhD; William Gradishar, MD

Roundtables

Managing Patients With HER2-Positive Metastatic Breast Cancer

06/17/2024

Ruta Rao, MD

William Gradishar, MD

Seth Wander, MD, PhD

In this video, a panel of experts discuss the management of patients with HER2-positive metastatic breast cancer, including updated results from the DESTINY-Breast03 trial.

In this video, a panel of...

06/17/2024

Oncology

Roundtables

Sequencing Antibody Drug Conjugates for Patients With HER2-Low Metastatic Breast Cancer

06/17/2024

Ruta Rao, MD

William Gradishar, MD

Seth Wander, MD, PhD

In this video, a panel of experts discuss the sequencing of antibody drug conjugates of patients with HER2-low metastatic breast cancer, including trastuzumab deruxtecan, sacituzumab govitecan, and datopotamab deruxtecan.

In this video, a panel of...

06/17/2024

Oncology

Recent News

News

National Analysis Provides Greater Insights in HER2-Low Metastatic Breast Cancer

09/29/2021

Findings from a national retrospective analysis of patients with HER2-low metastatic breast cancer were presented at the virtual 2021 ESMO Congress to exhibit distinct clinical outcomes.

Findings from a national...

09/29/2021

Oncology

News

Datopotamab Deruxtecan Approved for HR-Positive, HER2-Negative Breast Cancer

01/17/2025

Allison Casey ;

The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...

The US Food and Drug...

01/17/2025

Oncology

FDA Alerts

Sotorasib Plus Panitumumab Approved for Patients With KRAS G12C-Mutated Colorectal Cancer

01/17/2025

Stephanie Holland ;

Based on results from the phase 3 CodeBreaK 300 trial, the FDA has approved sotorasib plus panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer.

Based on results from the phase...

01/17/2025

Oncology

FDA Approval

FDA Approves Acalabrutinib With Bendamustine and Rituximab for Patients With Previously Untreated MCL

01/17/2025

Gina Tomaine ;

The FDA granted approval to acalabrutinib with bendamustine and rituximab for patients with previously untreated mantle cell lymphoma ineligible for autologous hematopoietic stem cell transplantation.

The FDA granted approval to...

01/17/2025

Oncology

News

Presence of Circulating Lymphoma Cells May Be Associated With Worse Survival Outcomes for Newly Diagnosed Patients With DLBCL

01/16/2025

Emily Estrada ;

Inferior survival outcomes are associated with presence of circulating lymphoma cells at time of de novo diffuse large B-cell lymphoma diagnosis, according to results from a retrospective cohort study.

Inferior survival outcomes are...

01/16/2025

Oncology

News

Ciltacabtagene Autoleucel Demonstrates Efficacy for Patients With R/R Multiple Myeloma in Real-World Population

01/15/2025

Emily Estrada ;

Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.

Treatment with ciltacabtagene...

01/15/2025

Oncology

News

Addition of Nab-Paclitaxel to Standard Gemcitabine and Cisplatin Did Not Significantly Improve Survival for Patients With Newly Diagnosed Biliary Tract Cancer

01/14/2025

Stephanie Holland ;

According to results from the phase 3 SWOG-S1815 study, the addition of nab-paclitaxel to gemcitabine plus cisplatin did not significantly improve survival outcomes for patients with newly diagnosed advanced biliary tract cancer.

According to results from the...

01/14/2025

Oncology

News

First-line Eribulin Plus Trastuzumab and Pertuzumab for Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer

01/14/2025

Stephanie Holland ;

According to results from the phase 3 EMERALD trial, eribulin plus trastuzumab and pertuzumab demonstrated promising efficacy as a first-line option for patients with HER2-positive locally advanced or metastatic breast cancer.

According to results from the...

01/14/2025

Oncology

News

Avelumab Plus Axitinib Demonstrates Long-Term Efficacy, Safety for Patients With Advanced Renal Cell Carcinoma

01/08/2025

Stephanie Holland ;

Final results from the phase 3 JAVELIN Renal 101 trial demonstrated that avelumab plus axitinib showed long-term efficacy and safety among patients with previously untreated advanced renal cell carcinoma.

Final results from the phase 3...

01/08/2025

Oncology

News

Neratinib Demonstrates Promising Efficacy for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

01/08/2025

Stephanie Holland ;

According to results from the phase 2 SUMMIT basket trial, neratinib demonstrated promising efficacy among patients with EGFR-mutated non-small cell lung cancer.

According to results from the...

01/08/2025

Oncology

News

Nivolumab Plus Ipilimumab Prolonged Progression-Free Survival for Patients with MSI-H/dMMR Metastatic Colorectal Cancer

01/06/2025

Stephanie Holland ;

Interim analysis results from the phase 3 CheckMate 8HW trial demonstrated that nivolumab plus ipilimumab prolonged progression-free survival compared to chemotherapy alone among patients with microsatellite instability-high or mismatch...

Interim analysis results from...

01/06/2025

Oncology